Unicycive Therapeutics, Inc. (UNCY)

Unicycive Therapeutics Earnings Call Transcripts

Fiscal Year 2026

• 25th Annual Needham Virtual Healthcare Conference

  Upcoming PDUFA for oxylanthanum carbonate could enable a differentiated, low pill burden therapy for hyperphosphatemia in dialysis patients, with strong clinical data and a focused commercialization plan. Financial runway and reimbursement strategies support near-term launch.

  Read full transcript →

Fiscal Year 2025

• H.C. Wainwright 4th Annual Kidney Virtual Conference

  OLC, a therapy for hyperphosphatemia in dialysis patients, faces a regulatory delay due to a third-party manufacturing issue, not drug safety or efficacy. Commercial launch is planned soon after approval, with strong funding and a focused sales strategy.

  Read full transcript →

Data Source: Quartr Last updated: Apr 15, 2026

Earnings call transcripts are provided by Quartr and are published within hours after each earnings call.

Update frequency:

Quarterly

Data Sources Report a data error

Stock Analysis Pro

Upgrade now for unlimited access to all data and tools.

Market Newsletter

Get a daily email with the top market news in bullet point format.